Bionure seeks to develop neuroprotective therapies for Multiple Sclerosis and other brain diseases based on the most recent discoveries in neuroscience and applied immunology. In order to aid such findings along the pathway to innovation, we will apply a systems biology approach whereby medical knowledge will be combined with the power of computers to better predict the efficacy of the therapies.
In order to benefit adequately from cutting edge discoveries, we maintain a network of collaborators from the most important universities and research centres from around the world. In particular, we maintain a close collaboration with the research groups from which the project has been spawned (The Neuroimmunology group of Hospital Clinic-IDIBAPS and combinatory chemistry unit at the CSIC).
The strategy at Bionure is to obtain the knowledge required to develop neuroprotective therapies by establishing partnerships with academic centres and clinical research organizations in Europe and the U.S.A.
Bionure is open to collaborate with academic groups and other biotech companies in EU or NIH research applications. Bionure is also willing to contribute its technology and know-how of preclinical and clinical development to other neuroprotective therapies.